Personnel Moves Archives - Page 41 of 42

Centinel Spine appoints new chief financial officer

Centinel Spine this week said it appointed Varun Gandhi as chief financial officer, effective August 17.

Gandhi succeeds Jeff Stello, who had served as interim chief financial officer since late 2018.

Prior to his appointment, Gandhi served as senior VP of corporate finance and strategic planning and GM of international at Centinel Spine. He previously served as VP of strategic planning and corporate finance at Small Bone Innovations, which was later acquired by Stryker.

“Varun Gandhi is a proven financial, strategic, and organizational leader in the orthopedics industry who has made particularly important contributions to Centinel Spine and its growth over the past several years. He knows our company and the spine market deeply. We look forward to Varun’s contributions to the next phase of growth for Centinel Spine,” CEO Steve Murray said in a news release.

Aerin Medical closes $48M financing, appoints new CEO

Aerin Medical announced today that it closed a $48 million equity financing and appointed Matt Brokaw as its new president & CEO.

Brokaw previously served in roles at Tusker Medical, Spirox, Entellus Medical, Stryker (NYSE:SYK), Acclarent, Johnson & Johnson (NYSE:JNJ) and Smith & Nephew (NYSE:SNN).

“Aerin is primed for its next phase of growth, propelled by non-invasive treatments embraced by patients, and in-office procedure options that are increasingly important to the ENT specialty,” Brokaw said in a news release. “I’m tremendously excited to join the team at this critical period, and I look forward to working in close partnership with the otolaryngology community and this experienced group of healthcare investors.”

New investor Questa Capital led the $48 million funding round, while OrbiMed and existing investor KCK Group also participated in the financing, according to the release.

Sunnvale, Calif.-based Aerin, a developer of tre…

Conformis names new marketing VP

Joint replacement implant maker Conformis (NSDQ:CFMS) announced that it appointed Farzin Kaghani as its new VP of U.S. marketing.

Khaghani, a veteran of more than 20 years in orthopedic and medtech sales and marketing, most recently served as president at NextStep Arthropedix, but before that, he spent more than 10 years at Conformis in a number of roles.

According to a news release, Khaghani also served as product director at Johnson & Johnson (NYSE:JNJ) unit DePuy Synthes for five years. Before that, he served as director of operations at Win Enterprises.

“We are very pleased to announce that Farzin Khaghani has rejoined our team as VP, U.S. marketing,” Conformis president & CEO Mark Augusti said in the release. “Farzin’s product expertise and track record of successfully supporting strategic goals and attracting new surgeon users to the Conformis family will help us continue our successful market expansion. I look forward to the co…

TransEnterix appoints CFO

Robotic surgery company TransEnterix (NYSE: TRXC) announced today that it has hired Shameze Rampertab as its news EVP and CFO.

“We are delighted to welcome Shameze to our team during this important time in TransEnterix’s journey,” TransEnterix CEo Anthony Fernando said in a news release. “His extensive experience at implementing financial strategies and sourcing equity and debt financing options will be invaluable as we continue towards our goals for 2020 and beyond. I am confident Shameze will make an immediate positive impact on the organization and help lead TransEnterix through its next phase of growth.”

Rampertab has over 20 years of financial leadership experience in the healthcare sector. He also spent time as an investment banker and sell-side equity research analyst. Most recently, he rose up to become interim CEO at animal health company Zomedica Pharmaceuticals.

TransEnterix recently reported tough but better-than-expected results for its seco…

Irish medtech startup AventaMed brings on U.S.-based CEO

Traditional ear tube surgery alternative developer AventaMed announced that it appointed U.S.-based Keith Jensen as its new president & CEO.

The Cork, Ireland-based medtech startup said in a news release that Jensen will succeed co-founder Olive O’Driscoll in the positions as he attempts to lead the company beyond its current startup phase and into the growth and commercialization phase, having already secured more than $6.2 million (€5.2 million) in funding.

Jensen previously held leadership roles at Boston Scientific, Cortek, InaVein and was president & CEO of Vascular Insights before his most recent position as senior VP of international business for the American Heart Association. O’Driscoll is set to assume an advisory consulting position and remain on the company’s board.

AventaMed develops the Solo Tympanostomy Tube Device (Solo TTD) for the quick and simple insertion of ear tubes without general…

Silk Road Medical appoints chief commercial officer

Stroke treatment developer Silk Road Medical (NSDQ:SILK) announced that it promoted Andrew Davis as its new chief commercial officer.

In the newly created role at the Sunnyvale, Calif.-based company, Davis is slated to oversee Silk Road Medical’s global commercialization efforts by establishing near-term priorities and setting the long-term strategic direction for the organization, according to a news release.

“Andy and his team have had a monumental role in our commercial success driving the safe adoption of [transcarotid artery revascularization] across the U.S.,” Silk Road Medical CEO Erica Rogers said in the release. “His contributions to the development of our sales team and commercial strategy have been vital to our organization. In his new role, we are confident that Andy will provide additional strategic direction and value and deliver meaningful and lasting results for Silk Road Medical.”

Davis joined the company as its first commercial le…

Eko names Humbarger as new SVP

Eko announced yesterday that it appointed Bryan Humbarger as its new senior vice president of commercial with an emphasis on sales.

The digital health sales veteran’s new role includes responsibilities for overseeing sales and commercial operations for Eko’s AI and telemedicine software platforms for health systems, practices and providers worldwide, according to a news release.

“Eko’s next generation of cardiac and pulmonary solutions are already making a difference for providers and their patients, and I am thrilled to bring my experience in cardiology and digital health to further accelerate the adoption of Eko’s technology,” Humbarger said in the release. “Being at the forefront of delivering what’s next in cardiovascular care is my passion, and I am thrilled to continue this journey at Eko, a company making a difference in how cardiac and pulmonary care is delivered.”

Oakland, Calif.-based Eko welcomes Humbarger on the back of FDA cleara…

CHF Solutions announces new president, COO

CHF Solutions (NSDQ:CHFS) recently announced that it has promoted Nestor Jaramillo Jr. to the president and COO spot at the company.

Jaramillo’s promotion was effective July 1.

Jaramillo has been at the Eden Prairie, Minn.-based fluid overload treatment developer since May 2019, focusing on commercial growth.

“Nestor has had a strong impact on our commercial success over the last 14 months,” said CHF Solutions CEO John Erb.

“Under Nestor’s leadership, we have expanded our strategy into critical care and pediatrics, including the recent launch of the Aquadex SmartFlow system for use in adult and pediatric patients weighing over 20 kg. I look forward to continuing to work with Nestor as the company improves the lives of patients suffering from fluid overload,” Erb said in a June 25 news release.

Before CHF, Jaramillo was president and CEO of Innerspace Neuro Solutions, a commercial-stage medtech company that developed, manufacture…

VisionCare names new CEO

Visual prosthetic device developer VisionCare announced today that Thomas Ruggia has been appointed as its new CEO, effective today.

Saratoga, Calif.-based VisionCare’s previous CEO and executive chairman of the board, Wolfgang Tolle, left the company to focus on new opportunities, according to a news release.

“We’re thrilled to welcome Tom to VisionCare,” VisionCare CEO Richard Powers said in a news release. “His nearly 20 years of ophthalmology business experience means he has a comprehensive and nuanced understanding of the health care environment in the U.S. and abroad, as well as significant experience in the development and commercialization of vision products with differing regulatory and pricing structures.

“Tom brings new energy to VisionCare at a pivotal time when we are poised to expand the reach and appeal of the CentraSight treatment program.”

Ruggia previously spent five years at Johnson & Johnson, most re…

Former Eli Lilly researcher joins Bigfoot Biomedical as chief medical officer

Bigfoot Biomedical has brought on Dr. Jim Malone — a 21-year clinical research veteran at Eli Lilly & Co. — as its chief medical officer, the diabetes treatment tech company said today.

Malone, an endocrinologist specializing in diabetes, also spent 12 years in clinical practice.

Get the full story on our sister site Drug Delivery Business News.

Inspire Medical names Ebeling as new COO

Obstructive sleep apnea therapy developer Inspire Medical Systems (NYSE:INSP) announced today that it appointed industry veteran Phil Ebeling as its new COO.

The company’s new COO is taking on responsibilities including oversight and leadership of operations, quality assurance, clinical research, regulatory affairs and business development activities, according to a news release.

Ebeling most recently served as VP & chief technology officer at Abbott (NYSE:ABT) after it acquired St. Jude Medical. He served for 10 years total between the two companies as a member of the executive team and corporate officer with both. He also spent 12 years in multiple senior positions at Boston Scientific (NYSE:BSX).

“I am thrilled to join the dynamic team at Inspire during this exciting period of robust growth highlighted by the recent positive advancements in reimbursement,” Ebeling said in the news release. “The ongoing development of Inspire therapy and futu…

Inspire Medical raises $10.7m, names new COO

Inspire Medical Systems (NYSE:INSP) announced today that it raised $10.7 million and named Phil Ebeling as its new chief operating officer.

According to a news release, Inspire entered into an underwriting agreement on June 3 with A.G.P./Alliance Global Partners in the offering of more than 7.6 million units consisting of one share of Inspire’s common stock and one Series F warrant to purchase a share, plus nearly 14.6 million pre-funded units that included one pre-funded warrant and one Series F warrant.

Underwriters also had a 45-day option to purchase up to an additional 3.3 million shares of common stock at 45¢ per share and/or up to 3.3 million additional Series F warrants. The offering closed on June 5 with the underwriter option exercised nearly in full, yielding gross proceeds of $11.5 million, turning into net proceeds worth $10.7 million.

The obstructive sleep apnea (OSA) therapy developer intends to use the net proceeds for research and …